New drug cocktail aims to outsmart resistant prostate cancer

NCT ID NCT04986423

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2b trial tests whether adding an experimental drug called ZEN003694 to the standard drug enzalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to abiraterone. About 200 men will be randomly assigned to receive either the combination or enzalutamide alone. The study separates patients based on how well they responded to prior abiraterone, and the main goal is to see if the combination delays cancer growth or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ZEN003694 (ZEN-3694) combined with enzalutamide (Xtandi)

What this could lead to

If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.

What could go wrong

This is a mid-stage trial with only 200 participants, so results may not confirm benefit. The drug combination may cause side effects or fail to improve progression-free survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, 230002, China

  • BRCR Global

    RECRUITING

    Plantation, Florida, 33322, United States

  • California Research Institute

    RECRUITING

    Los Angeles, California, 90027, United States

  • Chongqing Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Colorado Urology

    RECRUITING

    Lakewood, Colorado, 80228, United States

  • D&H Cancer Research Center, LLC

    RECRUITING

    Margate, Florida, 33063, United States

  • First Hospital of Shanxi Medical University

    RECRUITING

    Taiyuan, Shanxi, 030001, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Hematology Oncology Clinic

    WITHDRAWN

    Baton Rouge, Louisiana, 70809, United States

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450000, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410006, China

  • Innovative Clinical Research Institute

    RECRUITING

    Whittier, California, 90603, United States

  • Liaoning Cancer Hospital

    WITHDRAWN

    Shenyang, Liaoning, 110042, China

  • Maryland Oncology Hematology, P.A.

    RECRUITING

    Columbia, Maryland, 21044, United States

  • Messino Cancer Center

    RECRUITING

    Asheville, North Carolina, 28806, United States

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Northwest Cancer Specialists, P.C.

    RECRUITING

    Portland, Oregon, 97223, United States

  • Seattle Cancer Care Alliance

    RECRUITING

    Seattle, Washington, 98109, United States

  • Shanghai Tenth People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200072, China

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Texas Oncology - Central South

    RECRUITING

    Austin, Texas, 78731, United States

  • The First Affiliated Hospital of Xi'an Jiaotang University

    RECRUITING

    Xi'an, Shaanxi, 71000, China

  • The First Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, Fujian, 361003, China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94158, United States

  • University of Michigan Rogel Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Urology Associates, P.C.

    RECRUITING

    Nashville, Tennessee, 37209, United States

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Weill Cornell Medical College - New York Presbyterian Hospital

    COMPLETED

    New York, New York, 10065, United States

  • Zhejiang Provincial People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310014, China